Stay updated on Pembrolizumab as AML Post-Remission Treatment Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page.

Latest updates to the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page
- Check3 days agoChange DetectedDifference0.8%
- Check10 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.9%
- Check17 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check24 days agoNo Change Detected
- Check46 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.9%
- Check53 days agoChange DetectedDifference0.8%
- Check60 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed information about a study on pembrolizumab for treating acute myeloid leukemia in patients over 60, while adding a new collaborator and a revision number.SummaryDifference37%
Stay in the know with updates to Pembrolizumab as AML Post-Remission Treatment Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page.